Home/ Stocks/ PLX

Protalix BioTherapeutics, Inc. Common Stock

PLX XASE

$2.46 +0.03 (+1.23%) ▲ 15-min delayed

Open

$2.43

High

$2.47

Low

$2.42

Volume

670.2K

Market Cap

$196.59M

About Protalix BioTherapeutics, Inc. Common Stock

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 226 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$33.75M	$18.32M	$0.23
FY 2025	$52.74M	$-6,604,000	$-0.08
Q3 2025	$17.85M	$2.35M	$0.03
Q1 2025	$10.11M	$-3,619,000	$-0.05

Related Market News

No specific coverage for PLX yet. Check out our latest market news or earnings calendar.

Get PLX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Protalix BioTherapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.